ArticleBiomaterials research2023
Injectable hydrogel nanoarchitectonics with near-infrared controlled drug delivery for in situ photothermal/endocrine synergistic endometriosis therapy.
Article in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Recent Trends in Tissue Engineering Strategies for Uterine Endometrial Regeneration: a Systematic Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Pooled it
- An Injectable ROS-Responsive Nanozyme Hydrogel Regulates the Uterine Microenvironment to Prevent Intrauterine Adhesions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Nanomaterial Platforms for Endometriosis: A Systematic Review.Current medical science · 2026Review
- Integrative bioengineering strategies for endometrial regeneration: From biomaterials and stem cells to organoids and organ-on-a-chip technologies.Theranostics · 2026Review
- Nanotechnology strategies for endometrium health: Are we on the right track?Bioactive materials · 2025Review
- Fascinating Frontier, Nanoarchitectonics, as Method for Everything in Materials Science.Materials (Basel, Switzerland) · 2025Review
- The cutting-edge progress of novel biomedicines in ovulatory dysfunction therapy.Acta pharmaceutica Sinica. B · 2025Review
- Smart hydrogels for in situ tissue drug delivery.Journal of biomedical science · 2025Review
- Photothermal Release by Melanin-like Nanoparticles: Biomedical Applications.Journal of functional biomaterials · 2025Review
- Layer-by-Layer Nanoarchitectonics: A Method for Everything in Layered Structures.Materials (Basel, Switzerland) · 2025Review
- Fundamentals and Advances in Stimuli-Responsive Hydrogels and Their Applications: A Review.Gels (Basel, Switzerland) · 2025Review
- MXene/Doxorubicin Complex-Loaded Supramolecular Hydrogels for Near Infrared-Triggered Synergistic Cancer Therapy.Biomaterials research · 2025Article
- Recent development of nanotechnology-based approaches for gynecologic cancer therapy.Obstetrics & gynecology science · 2025Article
- Materials Nanoarchitectonics for Advanced Devices.Materials (Basel, Switzerland) · 2024Review
- Injectable Magnetic Hydrogel Incorporated with Anti-Inflammatory Peptide for Efficient Magnetothermal Treatment of Endometriosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Liquid-Liquid and Liquid-Solid Interfacial Nanoarchitectonics.Molecules (Basel, Switzerland) · 2024Review
- Bioengineering approaches for the endometrial research and application.Materials today. Bio · 2024Review
- Advances in Hydrogel-Based Drug Delivery Systems.Gels (Basel, Switzerland) · 2024Review
- Confined Space Nanoarchitectonics for Dynamic Functions and Molecular Machines.Micromachines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEndometriosis is a common gynecological disease in women of childbearing age. Commonly used treatment methods, such as endocrine and surgical therapies, display poor therapeutic effects with a high relapse probability. Thus, novel treatments for endometriosis are required.
methodsIn our study, polydopamine (PDA), letrozole (LTZ), and agarose (AG) hydrogels were combined to construct an injectable hydrogel with near-infrared controlled drug delivery named LTZ-PDA@AG hydrogel for endometriosis treatment. The release of letrozole can be accurately controlled by the near-infrared light intensity, exposure duration, polydopamine concentration, and hydrogel composition. Meanwhile, we isolated endometrial stromal cells from endometrium in patients with endometriosis, and constructed the rats' model of endometriosis to verify the biological effects of LTZ-PDA@AG hydrogel.
resultsOwing to the sufficiently deep penetration of near-infrared light, the LTZ-PDA@AG hydrogel displayed a high temperature increase for efficient photothermal therapy. In addition, high local temperatures can further enhance the diffusion and penetration of letrozole, thereby achieving excellent therapeutic effect in vivo. Importantly, the in vivo and vitro test demonstrated the capacity of the nanocomposite hydrogel for endocrine-photothermal synergistic therapy and the biocompatibility.
conclusionOur work proposes a novel concept for precision endometriosis therapy by photothermal-enhanced endocrine therapy for endometriosis, which is proposed for the first time for the treatment of endometriosis and demonstrates excellent potential for further clinical translation.
trial registrationNot applicable. LTZ-PDA@AG hydrogels were synthesized and displayed a high temperature increase for efficient photothermal therapy under NIR. The present study shows the capacity of the nanocomposite hydrogel for endocrine-photothermal synergistic therapy and the biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.